Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-Label Phase 4 Study of CREXONT® (Carbidopa and Levodopa) Extended Release Capsules in Parkinson's Disease Patients

NCT06765668 is registered in ClinicalTrials.gov with Impax Laboratories, LLC as lead sponsor.

NCT NCT06765668
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06765668 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-Label Phase 4 Study of CREXONT® (Carbidopa and Levodopa) Extended Release Capsules in Parkinson's Disease Patients
Lead sponsor
Impax Laboratories, LLC
Phase
Phase 4
Overall status
Recruiting
Start date
February 12, 2025
Completion date
August 6, 2026
Enrollment
220 (estimated)
Sites
27

Conditions

As the registry lists them; a condition with its own page is linked.

parkinson disease